Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

This one-time weight-loss drug leader has suffered several setbacks lately. It isn't wise to count out this veteran ...

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

Many Americans struggle with being overweight, social stigmas still prevent people from talking to doctors and seeking ...

While overall risk of macular degeneration remained low, a study suggests that GLP-1 drugs may have increased that risk in ...

Omada is trading publicly after 14 years of providing support to patients with weight-related chronic illnesses. Leadership sees the current moment as the perfect time for an IPO, as GLP-1 drugs such ...

A GROWING number of slimmers are trying to squeeze extra jabs out of empty Mounjaro pens in a risky bid to cut costs. The ...

Use of the weight-loss drug is rising among adolescents, but questions remain over long-term safety, access, and ...

To everyone’s surprise, the businessman got the cat out of the bag and confessed to the world how he lost an astounding 50 ...